Novavax, Inc. ( NVAX ) is Attracting Investor Attention: Here is What You Should Know
Recently, Zacks.com users have been paying close attention to Novavax (NVAX). This makes it worthwhile to examine what the stock has in store.
Novavax Q3 Earnings & Revenues Beat Estimates, '25 Sales View Raised
NVAX exceeds third-quarter expectations, boosted by a Sanofi milestone payment. It lifts its 2025 sales outlook.
Novavax ( NVAX ) Reports Q3 Loss, Beats Revenue Estimates
Novavax (NVAX) delivered earnings and revenue surprises of +42.59% and +77.85%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Anika Therapeutics ( ANIK ) Q3 Earnings and Revenues Top Estimates
Anika (ANIK) delivered earnings and revenue surprises of +100.00% and +0.06%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Top Stocks With Earnings This Week: Joby, IonQ, AMD and More - Palantir Technologies ( NASDAQ:PLTR )
Retail investors are preparing for another busy week of earnings season with more than 1,600 companies set to report through Friday. Here's a look at the names most likely to be on individual investors' radars. CIFR stock is soaring. Watch the real-time price action here.
Novavax ( NVAX ) Stock Sinks As Market Gains: Here's Why
In the latest trading session, Novavax (NVAX) closed at $8.52, marking a -2.07% move from the previous day.
Novavax ( NVAX ) Registers a Bigger Fall Than the Market: Important Facts to Note
Novavax (NVAX) closed the most recent trading day at $8.46, moving 1.51% from the previous trading session.
Novavax, Inc. ( NVAX ) Is a Trending Stock: Facts to Know Before Betting on It
Recently, Zacks.com users have been paying close attention to Novavax (NVAX). This makes it worthwhile to examine what the stock has in store.
Novavax ( NVAX ) Suffers a Larger Drop Than the General Market: Key Insights
Novavax (NVAX) reached $8.48 at the closing of the latest trading day, reflecting a -4.83% change compared to its last close.
Hedge Fund Shah Capital Urges Novavax To Consider Sale Amid Vaccine Rollout Struggles, Sees $5 Billion Potential - Novavax ( NASDAQ:NVAX )
Shah Capital is reportedly pressing Novavax Inc. ( NASDAQ:NVAX ) to consider a sale of the biotech firm, citing continued struggles in the rollout of its COVID-19 vaccine. The hedge fund holds a 7.2% stake and is the company's second-largest shareholder.
Investors Heavily Search Novavax, Inc. ( NVAX ) : Here is What You Need to Know
Recently, Zacks.com users have been paying close attention to Novavax (NVAX). This makes it worthwhile to examine what the stock has in store.
Novavax ( NVAX ) Stock Slides as Market Rises: Facts to Know Before You Trade
Novavax (NVAX) closed the most recent trading day at $9.08, moving 4.02% from the previous trading session.
Novavax ( NVAX ) Exceeds Market Returns: Some Facts to Consider
The latest trading day saw Novavax (NVAX) settling at $8.67, representing a +1.17% change from its previous close.
Here's Why Novavax ( NVAX ) is a Strong Momentum Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Here is What to Know Beyond Why Novavax, Inc. ( NVAX ) is a Trending Stock
Novavax (NVAX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Novavax ( NVAX ) Declines More Than Market: Some Information for Investors
Novavax (NVAX) concluded the recent trading session at $8.68, signifying a -2.2% move from its prior day's close.
Elizabeth Warren Says Measles Can Hit Record Highs, Slams RFK Jr.'s CDC Panel For Delaying Vaccine: 'How Does That Keep Our Kids Safe?' - Dynavax Technologies ( NASDAQ:DVAX ) , GSK ( NYSE:GSK )
Sen. Elizabeth Warren ( D-Mass. ) on Thursday criticized the Centers for Disease Control and Prevention's vaccine advisory panel following its controversial vote to delay the combined measles, mumps, rubella, and varicella or MMRV vaccine for children under 4 years old.
Here's Why Novavax ( NVAX ) Fell More Than Broader Market
Novavax (NVAX) closed at $8.39 in the latest trading session, marking a -1.99% move from the prior day.
MRNA Stock Rises as Updated COVID-19 Jab Shows Strong Immune Response
Moderna jumps after its updated formulation of Spikevax shows an over 8-fold increase in neutralizing antibodies against the LP.8.1 COVID-19 variant in phase IV study.
Robert Kennedy Jr. Packs CDC Panel With Vaccine Skeptics Ahead of Key Vote On COVID-19 Shots - Merck & Co ( NYSE:MRK ) , GSK ( NYSE:GSK )
Health and Human Services Secretary Robert F. Kennedy Jr. has added five new members to the Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices, just days before it reconvenes to vote on COVID-19 shots and other routine pediatric vaccine recommendations.
COVID-19 Vaccine Stocks Fall on Reports Linking Shots to Child Deaths
MRNA, BNTX, PFE and NVAX stocks fall as health officials reportedly plan to link COVID-19 vaccines to child deaths ahead of a key CDC meeting.
Pfizer, Moderna shares fall on report that Trump officials will link child deaths to Covid shots
The report says officials plan to include the claim in a presentation next week to a key vaccine panel that advises the CDC on shot access and coverage.
FDA Moves To Publicize Data On Pregnant Women's Covid Vaccine Side Effects - Novavax ( NASDAQ:NVAX ) , Moderna ( NASDAQ:MRNA ) , Pfizer ( NYSE:PFE )
FDA seeks to lift privacy rules on Covid vaccine data for pregnant women to reveal more potential side effects. Pfizer, Moderna and Novavax defended their vaccines after Trump's transparency call, citing safety data for pregnant women. Get the data-driven signals to profit from September ...
Novavax, Inc. ( NVAX ) is Attracting Investor Attention: Here is What You Should Know
Zacks.com users have recently been watching Novavax (NVAX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Florida Chooses 'Medical Freedom' As State Plans To End Vaccine Mandates, Even For Schools: Experts Warn Of 'Major Disaster' - Merck & Co ( NYSE:MRK ) , GSK ( NYSE:GSK )
Florida plans to end all statewide vaccine mandates, even those required for school attendance, framing the move as a defense of individual liberties, which has since received pushback from public health experts.
Bernie Sanders Demands Health Secretary RFK Jr.'s Resignation As CDC Leadership Crisis Deepens - Merck & Co ( NYSE:MRK ) , GSK ( NYSE:GSK )
Senator Bernie Sanders ( I-VT ) called for Health and Human Services Secretary Robert F. Kennedy Jr.'s resignation on Saturday, citing Kennedy's "dangerous policies" that are "endangering the health of the American people."
Boyd Gaming and Shoe Carnival have been highlighted as Zacks Bull and Bear of the Day
Boyd Gaming surges on strong earnings and growth plans, while Shoe Carnival struggles with sliding sales and weaker momentum.
FDA Approves Updated COVID-19 Vaccines but With Restrictions
FDA clears updated COVID-19 vaccines from Pfizer, Moderna and Novavax but limits access to older adults and high-risk groups.
Why Novavax ( NVAX ) is a Top Momentum Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
RFK Jr. Rescinds Emergency Authorizations For COVID-19 Vaccines - Novavax ( NASDAQ:NVAX ) , Moderna ( NASDAQ:MRNA ) , Pfizer ( NYSE:PFE ) , BioNTech ( NASDAQ:BNTX )
FDA approves updated Pfizer, Moderna, and Novavax Covid vaccines for high-risk individuals. Pfizer-BioNTech Covid vaccine doses exceed 5 billion distributed globally. The market is reacting to NVIDIA's earnings. Learn how to time your next trade here → Health and Human Services Secretary Robert ...
FDA ends broad Covid vaccine authorization as RFK Jr. limits access to immunizations
It's unclear how easily patients without high risk factors will be able to get a Covid shot, and whether insurance plans will still cover them.
Novavax, Inc. ( NVAX ) Is a Trending Stock: Facts to Know Before Betting on It
Novavax (NVAX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Trump Administration Plans To Pull COVID-19 Vaccines Off Market 'Within Months' - Moderna ( NASDAQ:MRNA ) , BioNTech ( NASDAQ:BNTX )
RFK Jr.'s adviser says COVID-19 vaccines could be pulled from the U.S. market within months. MIT professor critical of mRNA shots named to lead federal vaccine task force. See the seasonal trading strategy that's beating the S&P 500 by 6X this year. Details here →
What the Options Market Tells Us About Novavax - Novavax ( NASDAQ:NVAX )
Investors with a lot of money to spend have taken a bearish stance on Novavax NVAX. We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga. Whether these are institutions or just wealthy individuals, we don't know.
Novavax Shares Are Trading Higher Thursday: What's Going On? - Novavax ( NASDAQ:NVAX )
Novavax issues $225 million of 2031 convertible notes, including $175.3 million exchanged for 2027 notes and $49.7 million in new funding. The new notes convert at $11.14 per share, a 27.5% premium to the company's last closing price.
La-Z-Boy Posts Downbeat Q1 Results, Joins James Hardie Industries, Alcon And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session - Celldex Therapeutics ( NASDAQ:CLDX ) , Alcon ( NYSE:ALC )
U.S. stock futures were slightly lower this morning, with the S&P 500 futures falling around 0.1% on Wednesday. Shares of La-Z-Boy Incorporated LZB fell sharply in pre-market trading as the company reported weaker-than-expected financial results for the first quarter of fiscal 2026.
Investors Heavily Search Novavax, Inc. ( NVAX ) : Here is What You Need to Know
Novavax (NVAX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
FDA may pull authorization of Pfizer's Covid vaccine for children under 5
The potential move to rescind authorization of Pfizer's vaccine could leave some kids in the U.S. with no available shots against Covid.
CDC Shooting Linked To Suspect's COVID-19 Vaccine Beliefs, Former Staff Blame RFK Jr. Hostility Toward Agency - Moderna ( NASDAQ:MRNA ) , BioNTech ( NASDAQ:BNTX )
CDC shooter's writings revealed anti-vaccine beliefs and distrust of COVID-19 shots. The NIH chief says that mRNA vaccines lack viability due to public distrust. The next 100%+ earnings move could hit this month. See how to find it live on Wednesday → A group of former U.S.
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
FDA May Not Renew Pfizer's Authorization For Covid Shots In Younger Children, Moderna Prepares To Boost Supply - Moderna ( NASDAQ:MRNA ) , Pfizer ( NYSE:PFE )
Only 5.6% of children aged 6 months to 4 years old are vaccinated against COVID-19, CDC says. The FDA may not renew Pfizer's pediatric COVID-19 vaccine authorization for the 2025 season. This simple system has nailed 1,000+ post-earnings winners. Get in before Q3 trades take off →
Vinay Prasad's Comeback To FDA Sparks Debate Over Regulatory Direction - Cabaletta Bio ( NASDAQ:CABA ) , Moderna ( NASDAQ:MRNA )
Vinay Prasad returns as FDA's CBER head days after resigning amid Sarepta drug controversy. Analysts see a possible softer stance on rare disease therapies under Prasad. Get ahead of next week's CPI & PPI with Chris Capre's live trading strategy session this Sunday. Register Now →
Baculovirus Expression System Market Poised for Significant Growth, Estimate to Hit USD 781.8 Million by 2032 | Coherent Market Insights
Burlingame, CA, Aug. 08, 2025 ( GLOBE NEWSWIRE ) -- The global Baculovirus Expression System Market is estimated to be valued at USD 436.0 Mn in 2025 and is expected to reach USD 781.8 Mn in 2032, exhibiting a compound annual growth rate ( CAGR ) of 8.7% from 2025 to 2032.
NVAX Stock Gains on Q2 Earnings & Sales Beat, Ups '25 Sales View
Novavax tops Q2 estimates and lifts 2025 sales forecast as Sanofi takes over global rollout of its COVID vaccine.
Novavax ( NVAX ) Profit Jumps on Milestone
Novavax ( NASDAQ:NVAX ) , known for its protein-based vaccine technology, released its second quarter fiscal 2025 results on August 6, 2025. The standout news was a return to profitability on a GAAP basis, driven by significant partnership milestone payments, most notably a $175 million payment ...
Why Is Novavax Stock Soaring Wednesday? - Novavax ( NASDAQ:NVAX )
Q2 sales of $239 million beat the consensus of $156.29 million; EPS of $0.62 vs est. loss of $0.05. FY25 guidance raised to $1 billion-$1.05 billion from $975 million-$1.025 billion; Wall Street est. was $1.039 billion. The market's back, and these 3 income stocks are thriving. See them here→
Novavax ( NVAX ) Q2 Earnings and Revenues Top Estimates
Novavax (NVAX) delivered earnings and revenue surprises of +985.71% and +102.74%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Novavax Stock Dips As Moderna's Woes Weigh On Vaccine Sector - Novavax ( NASDAQ:NVAX )
Shares of Novavax are trading lower Friday morning. The stock appears to be caught in a downdraft affecting COVID-19 vaccine makers after rival Moderna reported disappointing Q2 results. Get special access to three exclusive "Top 10 Stocks" power lists today, updated daily.
Novavax ( NVAX ) Sees a More Significant Dip Than Broader Market: Some Facts to Know
In the most recent trading session, Novavax (NVAX) closed at $6.85, indicating a -2.28% shift from the previous trading day.
Here is What to Know Beyond Why Novavax, Inc. ( NVAX ) is a Trending Stock
Zacks.com users have recently been watching Novavax (NVAX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
